Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31–June 4, in Chicago. The event will feature plenary sessions, oral abstracts, education, and special sessions in both in-person and online meeting formats.
MSK experts will be available to comment on their innovative research on topics such as rectal cancer, renal cancer, sarcoma, head and neck cancer, and more:
- Andrea Cercek, MD, gastrointestinal oncologist, will present updated results for locally advanced mismatch repair deficient (dMMR) rectal cancer.
- Robert Motzer, MD, genitourinary oncologist, will present significant results from a phase III trial regarding immunotherapy-based regimens in patients with advanced renal cell carcinoma.
- William Tap, MD, will present results regarding the efficacy, safety, and patient-reported outcomes from the phase III trial of vimseltinib for the treatment of tenosynovial giant cell tumor.
- Neil Segal, MD, PhD, gastrointestinal oncologist, will present results from a phase 1/2 study regarding the combination of a human costimulatory bispecific with cemiplimab in patients with advanced solid tumors.
For more information and to set up interviews with MSK experts, contact Rebecca Williams, Manager of Media Relations, at williamr@mskcc.org. Follow the meeting live on Twitter using the hashtag #ASCO24 and follow MSK on Twitter at @MSKCancerCenter
